S3 guidelines on pulmonary disease in cystic fibrosis. Module 1: diagnostics and therapy after initial detection of Pseudomonas aeruginosa

被引：7

作者：

Mueller, F. -M.

Bend, J. ^{[1
]}

Huttegger, I. ^{[2
]}

Moeller, A. ^{[3
]}

Schwarz, C. ^{[4
]}

Abele-Horn, M.

Ballmann, M. ^{[5
]}

Bargon, J. ^{[6
]}

Baumann, I. ^{[7
]}

Bremer, W. ^{[8
]}

Bruns, R. ^{[9
]}

Brunsmann, F. ^{[10
]}

Fischer, R. ^{[11
]}

Geidel, C. ^{[12
]}

Hebestreit, H. ^{[13
]}

Hirche, T. O. ^{[14
]}

Hogardt, M. ^{[15
]}

Illing, S. ^{[16
]}

Koitschev, A. ^{[17
]}

Kohlhaeufl, M. ^{[18
]}

Mahlberg, R. ^{[19
]}

Mainz, J. G. ^{[20
]}

Pfeiffer-Auler, S. ^{[8
]}

Puderbach, M. ^{[21
]}

Riedler, J. ^{[22
]}

Schulte-Hubbert, B. ^{[23
]}

Sedlacek, L. ^{[24
]}

Sitter, H. ^{[25
]}

Smaczny, C. ^{[26
]}

Staab, D. ^{[4
]}

Tuemmler, B. ^{[27
]}

Vonberg, R. -P. ^{[24
]}

Wagner, T. O. F. ^{[26
]}

Zerlik, J. ^{[28
]}

Rietschel, E.

机构：

[1] Mukoviszidose Inst, Bonn, Germany

[2] Paracelsus Med Privatuniv, Univ Klin Kinder & Jugendheilkunde, Salzburg, Austria

[3] Univ Zurich, Fachbereich Pneumol, Zurich, Switzerland

[4] Charite, Christiane Herzog Zentrum, D-13353 Berlin, Germany

[5] DRK Kinderklin Siegen, Siegen, Germany

[6] St Elisabethen Krankenhaus Frankfurt, Katharina Kasper gGmbH, Frankfurt, Germany

[7] Heidelberg Univ, Hals Nasen Ohrenklin, D-69115 Heidelberg, Germany

[8] Mukoviszidose eV, Bonn, Germany

[9] Ernst Moritz Arndt Univ Greifswald, Zentrum Kinder & Jugendmed, Univ Med, Greifswald, Germany

[10] Charite, D-13353 Berlin, Germany

[11] Mukoviszidose Zentrum Munchen West, Munich, Germany

[12] Univ Kinderklin Wurzburg, Wurzburg, Germany

[13] Deutsch Klin Diagnost GmbH, Zentrum Pneumol Allergol Schlaf & Beatmungsmed, Wiesbaden, Germany

[14] Klinikum Johann Wolfgang Goethe Univ, Inst Med Mikrobiol & Krankenhaushyg, Frankfurt, Germany

[15] Klinikum Stuttgart, CF Zentrum Jugendl Erwachsene, Olgahosp, Stuttgart, Germany

[16] Klinikum Stuttgart Standort Olgahosp, Klin Hals Nasen Ohrenkrankheiten, Stuttgart, Germany

[17] Zentrum Pneumol & Thoraxchirurg, Klin Schillerhohe, Stuttgart, Germany

[18] Klinikum Mutterhaus Borromaerinnen, Innere Med, Trier, Germany

[19] Univ Klinikum, Mukoviszidosezentrum Padiat Pneumol, Jena, Germany

[20] Hufeland Klinikum GmbH, Abt Diagnost & Intervent Radiol, Bad Langensalza, Germany

[21] Kardinal Schwarzenbergsches Krankenhaus, Schwarzach, Austria

[22] Univ Klinikum Dresden, Med Klin & Poliklin, Dresden, Germany

[23] Hannover Med Sch, Inst Med Mikrobiol & Krankenhaushyg, Hannover, Germany

[24] Univ Marburg, Inst Theoret Med, Marburg, Germany

[25] Goethe Univ Frankfurt, Univ Klinikum, Zentrum Inneren Med Schwerpunkt Pneumol & Allerge, D-60054 Frankfurt, Germany

[26] Hannover Med Sch, Klin Forschergrp OE 6710, Klin Padiat Pneumol & Neonatol, Hannover, Germany

[27] Altonaer Kinderkrankenhaus gGmbH, Abt Physiotherapie, Hamburg, Germany

[28] Univ Cologne, Mukoviszidosezentrum, Klin Kinder & Jugendmed, Cologne, Germany

来源：

MONATSSCHRIFT KINDERHEILKUNDE | 2015年 / 163卷 / 06期

关键词：

Cystic fibrosis; Colonization; Eradication; Antibodies; Antibiotics; BRONCHOALVEOLAR LAVAGE; ERADICATION THERAPY; INHALED TOBRAMYCIN; YOUNG-CHILDREN; COLONIZATION; INFECTION; TRIAL; ACQUISITION; REGIMENS;

D O I：

10.1007/s00112-015-3354-3

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Cystic fibrosis (CF) is one of the most frequent autosomal recessive inherited diseases in the Caucasian population. A genetic defect in the CFTR gene leads to a reduction in chloride ion transport in cell membranes. The resulting dehydration of the wet epithelial film causes a reduction in secretion clearance. The consequence is a multiorgan disease. The pulmonary manifestation with chronic infections and inflammation is the leading cause of death. Acute and chronic infections caused by Pseudomonas aeruginosa (PA) can lead to a decline in lung function and have a direct negative effect on the chances of survival. The development of the first clinical S3 guideline for cystic fibrosis aims at standardizing and optimizing the diagnostics and therapy in Germany, Austria and Switzerland after the initial detection of P. aeruginosa. Simultaneously, this should provide an impulse for further research activities and developments of guidelines. On the basis of a Cochrane review a comprehensive up to date literature search was carried out for the period from 1995 to November 2011 (updated September 2014). Of the resulting 286 original papers, 6 randomized clinical trials and 8 additional eradication trials with low evidence were identified as relevant and were evaluated. Experts from 13 scientific and medical societies and associations evaluated the evidence by means of these original articles and with the help of national and international guidelines and consensus documents as a basis for the formulation of 36 recommendations in a nominal group process. The evaluation of the eradication studies demonstrated that early antibiotic eradication therapy is effective for patients with CF. Which therapy regimen is the most promising, cannot be decided due to a limited number of comparative studies. After evaluation of all the evidence the following core recommendations are given: the early eradication should be carried out by means of inhaled tobramycin for 4 weeks or by means of oral ciprofloxacin combined with inhaled colistin for 3 weeks. In cases where inhalation is not possible, an intravenous combination therapy should be taken into consideration as a possibility. If a therapy with inhalative and oral antibiotics does not lead to eradication, a combination therapy should be carried out with intravenous antibiotics and inhalative colistin. A sequential combination of intravenous and inhalative antibiotics is recommended for a pulmonary exacerbation and initial detection of PA. The early eradication therapy of PA is effective in cystic fibrosis and can be carried out according to the current guidelines. In the studies available no superiority of one particular therapy regimen could be shown. Further comparative studies as well as studies on the involvement of the upper respiratory tract should be performed in the future.

引用

页码：590 / 599

页数：10

共 31 条

[1] Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials [J].